Former President Donald Trump has boasted in recent months about “Right To Try,” a law he signed in 2018. It’s aimed at boosting terminally ill patients’ access to potentially lifesaving medications not yet approved by the Food and Drug Administration.
12 people changing the course of the Chinese biopharma industry
From antibody-drug conjugates to immuno-oncology checkpoint inhibitors, China is the world’s most closely watched rising biotechnology power. The growth of China’s industry can be attributed
October 7, 2024